1. Improvement in Overall Survival With Carfilzomib ...
17/1/2018 · In the ASPIRE study of carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide plus dexamethasone (Rd) in patients with relapsed or refractory multiple myeloma, progression-free survival was significantly improved in the carfilzomib group (hazard ratio, 0.69; two-sided P .001). This prespecified analysis reports final overall survival (OS) data and updated safety …
2. Response and progression-free survival according to ...
4/4/2018 · In ASPIRE, carfilzomib, lenalidomide, and dexamethasone (KRd) significantly improved progression-free survival (PFS) and response rates versus lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma. Per protocol, patients received KRd for a maximum of 18 cycles followed by Rd to progression, so the benefit/risk profile of KRd to progression was not established.
3. Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed ...
6/12/2014 · In this study, the addition of carfilzomib to lenalidomide and dexamethasone improved response rates and overall survival among patients with ... (ASPIRE) study is provided in the Supplementary ...
4. Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed ...
6/12/2014 · Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma A. Keith Stewart, ... (ASPIRE) study is provided in the Supplementary Appendix, available at NEJM.org.
5. Carfilzomib, lenalidomide, and dexamethasone in patients ...
15/5/2017 · A primary analysis of the ASPIRE study found that the addition of carfilzomib to lenalidomide and dexamethasone (carfilzomib group) significantly improved progression-free survival (PFS) compared with lenalidomide and dexamethasone alone (control group) in …
6. Phase 3 Study Comparing Carfilzomib, Lenalidomide, and ...
4/3/2010 · Dimopoulos MA, Stewart AK, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel D, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak A, San-Miguel J, Ludwig H, Palumbo A, Obreja M, Aggarwal S, Moreau P. Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study.
7. Response and progression-free survival according to ...
Background: In ASPIRE, carfilzomib, lenalidomide, and dexamethasone (KRd) significantly improved progression-free survival (PFS) and response rates versus lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma. Per protocol, patients received KRd for a maximum of 18 cycles followed by Rd to progression, so the benefit/risk profile of KRd to progression was not established.
8. Efficacy and safety of carfilzomib-based regimens in frail ...
9/11/2020 · Carfilzomib (K) is an irreversible proteasome inhibitor approved for use in combination with lenalidomide plus dexamethasone (KRd27 mg/m 2 twice-weekly carfilzomib at 27 mg/m 2) or dexamethasone (Kd twice-weekly carfilzomib at 56 mg/m 2 or once-weekly carfilzomib at 70 mg/m 2) for the treatment of relapsed and/or refractory MM (RRMM). 11 The pivotal phase 3 ASPIRE trial …
9.
10.
Response and progression-free survival according to ...
11. The role of carfilzomib in relapsed/refractory multiple ...
8/6/2021 · Dosing of carfilzomib was similar to the ASPIRE study, 20 mg/m 2 with ramp up to 27 mg/m 2 beginning on cycle 1 day 8; pomalidomide was 4 mg on days 1–21; and dexamethasone was given 40 mg weekly. The MTD was dose level 1, likely reflecting the extensive treatment history …
12. Carfilzomib and dexamethasone versus bortezomib and ...
5/12/2015 · The ongoing randomised phase 2 S1304 study (NCT01903811), which is comparing carfilzomib 20 mg/m 2 and 27 mg/m 2 plus dexamethasone versus carfilzomib 20 mg/m 2 and 56 mg/m 2 plus dexamethasone in patients with relapsed or refractory multiple myeloma, will provide important information about the relative efficacy and safety of these doses.
13. Final ASPIRE Results Confirm Survival Benefit With ...
1/3/2018 · According to final results from the phase III ASPIRE study assessing patients with relapsed/refractory multiple myeloma (MM), adding the proteasome inhibitor carfilzomib to a lenalidomide and dexamethasone regimen improves response rates and overall survival (OS), without increasing the risk of adverse events (AEs).
14.
The ASPIRE clinical trial was conducted in 2015 to assess the efficacy of carfilzomib, in addition to lenalidomide and dexamethasone, in patients with relapsed Multiple Myeloma (MM). The addition of carfilzomib resulted in a significant improvement in progression free survival (PFS). A subset of Multiple Myeloma (MM) patients with cytogenetic abnormalities, such as translocations (4;14), (14 ...
15. ASH 2014: Phase III ASPIRE study of carfilzomib ...
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Jeffery Matous ((Colorado Blood Cancer Institute, Denver, CO) discusses the randomised, o...
16. ASPIRE study: Carfilzomib potent addition to multiple ...
Visit http://www.ecancer.org for more.Prof Stewart (Mayo Clinic, Scottsdale, USA) talks to ecancertv at ASH 2014 about the phase III ASPIRE study looking at ...
17. Phase 3 A.R.R.O.W. Study Of Once-Weekly KYPROLIS ...
The A.R.R.O.W. (RAndomized, Open-label, Phase 3 Study in Subjects with Relapsed and Refractory Multiple Myeloma Receiving Carfilzomib in Combination with Dexamethasone, Comparing Once-Weekly versus Twice-weekly Carfilzomib Dosing) trial evaluated approximately 478 patients with relapsed and refractory multiple myeloma who have received at least two but no more than three prior therapies ...
18. Phase III ASPIRE study of carfilzomib, lenalidomide and ...
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Jeffery Matous (Colorado Blood Cancer Institute, Denver, CO) discusses the randomised, op...
19. Oncology Data Advisor - Carfilzomib for Frail Patients ...
12/11/2020 · Carfilzomib-based regimens are safe and effective for frail patients with relapsed/refractory multiple myeloma. ... According to the results of a new study, therapeutic combinations containing carfilzomib are safe and effective for frail patients with relapsed/refractory ...
20. A clinical update on the role of carfilzomib in the ...
Carfilzomib is a new proteasome inhibitor which, in contrast to the reversible binding of bortezomib, binds irreversi-bly and selectively to its target: the chymotrypsin-like activity of the 20S proteasome. By inhibiting proteasome function it stops proteolysis leading to
